{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-007834","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2026-10-14T12:15:14+00:00","discovered_at":"2026-10-14T12:20:00.133702+00:00","generated_at":"2026-10-14T12:20:05.009487+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Valion Bio touts CDMO Velocity Bioworks as Section 232 tariffs hit imports up to 100%","bullets":["Velocity Bioworks is Valion's wholly owned CDMO in San Antonio, offering process development, analytical services and early-phase GMP drug substance manufacturing.","Microbial GMP manufacturing at scales up to 200 liters; GMP mammalian capabilities also maintained for biologics through early clinical development.","New Section 232 pharmaceutical framework imposes tariffs of up to 100% on certain imported patented drugs and ingredients, effective September 29, 2026.","Velocity supports Valion's lead candidate Entolimod, in development as a potential medical countermeasure for Acute Radiation Syndrome.","Interim CEO Dean Zikria said Valion welcomes partner discussions; no new contracts, customers or financial impact were disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-007834","json":"https://secwatch.observer/filing/0001683168-26-007834.json","markdown":"https://secwatch.observer/filing/0001683168-26-007834.md","text":"https://secwatch.observer/filing/0001683168-26-007834.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000168316826007834/0001683168-26-007834-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000168316826007834/valion_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-14T12:20:05.009487+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}